Baede, VO; Barray, A; Tavakol, M; Lina, G; Vos, MC; Rasigade, J-P
(2022)
Nasal microbiome disruption and recovery after mupirocin treatment in Staphylococcus aureus carriers and noncarriers.
Sci Rep, 12 (1).
p. 19738.
ISSN 2045-2322
https://doi.org/10.1038/s41598-022-21453-4
SGUL Authors: Lindsay, Jodi Anne
Abstract
Nasal decolonization procedures against the opportunistic pathogen Staphylococcus aureus rely on topical antimicrobial drug usage, whose impact on the nasal microbiota is poorly understood. We examined this impact in healthy S. aureus carriers and noncarriers. This is a prospective interventional cohort study of 8 S. aureus carriers and 8 noncarriers treated with nasal mupirocin and chlorhexidine baths. Sequential nasal swabs were taken over 6 months. S. aureus was detected by quantitative culture and genotyped using spa typing. RNA-based 16S species-level metabarcoding was used to assess the living microbial diversity. The species Dolosigranulum pigrum, Moraxella nonliquefaciens and Corynebacterium propinquum correlated negatively with S. aureus carriage. Mupirocin treatment effectively eliminated S. aureus, D. pigrum and M. nonliquefaciens, but not corynebacteria. S. aureus recolonization in carriers occurred more rapidly than recolonization by the dominant species in noncarriers (median 3 vs. 6 months, respectively). Most recolonizing S. aureus isolates had the same spa type as the initial isolate. The impact of mupirocin-chlorhexidine treatment on the nasal microbiota was still detectable after 6 months. S. aureus recolonization predated microbiota recovery, emphasizing the strong adaptation of this pathogen to the nasal niche and the transient efficacy of the decolonization procedure.
Item Type: |
Article
|
Additional Information: |
© The Author(s) 2022
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
Keywords: |
Humans, Mupirocin, Staphylococcus aureus, Chlorhexidine, Prospective Studies, Cohort Studies, Carrier State, Staphylococcal Infections, Microbiota, Humans, Staphylococcus aureus, Staphylococcal Infections, Chlorhexidine, Mupirocin, Cohort Studies, Prospective Studies, Carrier State, Microbiota, Carrier State, Chlorhexidine, Cohort Studies, Humans, Microbiota, Mupirocin, Prospective Studies, Staphylococcal Infections, Staphylococcus aureus |
SGUL Research Institute / Research Centre: |
Academic Structure > Infection and Immunity Research Institute (INII) |
Journal or Publication Title: |
Sci Rep |
ISSN: |
2045-2322 |
Language: |
eng |
Dates: |
Date | Event |
---|
17 November 2022 | Published | 27 September 2022 | Accepted |
|
Publisher License: |
Creative Commons: Attribution 4.0 |
Projects: |
Project ID | Funder | Funder ID |
---|
547001006 | ZonMw | UNSPECIFIED | 16-JPEC-0006 | Agence Nationale de la Recherche | UNSPECIFIED |
|
PubMed ID: |
36396730 |
Web of Science ID: |
WOS:000885172100098 |
|
Go to PubMed abstract |
URI: |
https://openaccess.sgul.ac.uk/id/eprint/115990 |
Publisher's version: |
https://doi.org/10.1038/s41598-022-21453-4 |
Statistics
Item downloaded times since 11 Jan 2024.
Actions (login required)
|
Edit Item |